Considerations for the Future of Biosimilars in the Treatment of Retinal Disorders

EP: 1.How Biosimilars are Different Than Their Reference Products

EP: 2.Post-Market Surveillance of Biosimilars

EP: 3.Purity and Safety Standards for Biosimilars

EP: 4.Bridging Knowledge Gaps Regarding Biosimilars in the Treatment of Retinal Disorders

EP: 5.Clinical Findings for Biosimilars in the Treatment of Retinal Disorders

EP: 6.Biosimilar Indications and Routes of Administration

EP: 7.Practical Implications of Increased Utilization of Biosimilars in Practice

Now Viewing

EP: 8.Considerations for the Future of Biosimilars in the Treatment of Retinal Disorders

Carl D. Regillo, MD: [What are your] take-home messages for patients and providers?

Jennifer I. Lim, MD: For biosimilars, the regulatory process is significantly stringent enough for me to have the confidence that this biosimilar is equivalent to the reference drug. My take-home message to physicians is that the data are strong, the data are there and are reasonable. This is a biosimilar drug equivalent to the reference product.

Carl D. Regillo, MD: I’ll echo that and say understanding the process helps in our confidence that we have a good product that we can use safely for our patients. The same goes for patients. You said at 1 point that sometimes generic is a dirty word. Who knows? Biosimilar may [also be thought of as] dirty, but it shouldn’t because the FDA is there. This process is not new. As you said, in medicine, biosimilars have been around for quite some time, and there’s a good mechanism in place to prove and for proper surveillance of the products in practice.

Jennifer I. Lim, MD: Exactly. We must remember the nocebo effect. You must have that positive framing—not just from us but from our entire staff—so patients get the right message.

Carl D. Regillo, MD: Excellent.

Transcript edited for clarity